ArticleFrontiers in reproductive health2026
Residual risk of HIV, HBV, and HCV transmission through blood transfusion in Borgou, Benin, 2023-2025.
Article in Frontiers in reproductive health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Blood transfusion is a cornerstone of modern healthcare, particularly in maternal and pediatric care. However, it continues to carry a residual risk of transmitting transfusion-transmissible infections (TTIs), especially human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). Quantifying this residual risk is critical for optimizing transfusion safety, particularly in resource-limited settings. This study aimed to estimate the residual risk of HIV, HBV, and HCV transmission among blood donors in the Borgou department of Benin. Methods: A retrospective cohort study of repeat donors was conducted from January 2023 to December 2025 among repeat blood donors in Borgou. Serological screening was performed using enzyme-linked immunosorbent assay (ELISA) with Bio-Rad® kits. Residual risk was estimated using the Schreiber model based on incidence/window period methodology. Data were analyzed using SPSS software, and associations were assessed using the Chi-square test, with statistical significance set at Results: A total of 11,113 repeat donors were included, with a marked male predominance (male-to-female ratio: 14.14). The majority were aged 18-30 years (72%) and were students (54%). Overall, 145 incident infections were identified. Incidence rates per 100,000 donor-years were 5.98 for HIV, 350.28 for HBV, and 77.84 for HCV. No significant association was observed between HIV incidence and sociodemographic characteristics. In contrast, HBV and HCV incidences were significantly associated with age ( Conclusion: Although the residual risk of TTIs in Borgou is lower than that reported in several sub-Saharan African settings, it remains substantially higher than in high-income countries. These findings highlight the urgent need to strengthen donor selection strategies, enhance targeted health education, and implement more sensitive screening technologies, such as nucleic acid testing, to further improve blood safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.